5 Psychiatry Headlines You Missed in April 2026

April 2026 in psychiatry was defined by regulatory expansion, early-stage innovation, and emerging questions around how patients access mental health care. The US Food and Drug Administration (FDA) expanded the label for lumateperone (Caplyta) to include relapse prevention in schizophrenia. A White House executive order accelerated psychedelic research through coordinated action with the FDA and Drug Enforcement Administration (DEA), while clinical trials advanced rapid-acting and mechanism-driven approaches such as GH001. At the same time, increasing reliance on ChatGPT for mental health guidance raised new ethical and clinical oversight concerns for psychiatrists.

This month in review spotlights the 5 top psychiatry news stories in April 2026.

FDA Update: Extended Lumateperone Label for Schizophrenia

Lumateperone sNDA Approved with Relapse Prevention Data in Schizophrenia

The FDA approved a supplemental New Drug Application (NDA) for lumateperone, expanding its schizophrenia label to include relapse prevention. In the randomized withdrawal phase 3 trial, patients stabilized on lumateperone 42 mg had a 63% lower relapse risk versus placebo (HR, 0.37; P =.0002), with 84% remaining relapse-free at 6 months. Johnson & Johnson reported favorable time to relapse and discontinuation outcomes.

White House Push for Psychedelic Research

White House Order Accelerates Psychedelic Research for Mental Illness, With Gus Alva, MD

A White House executive order signed by Donald Trump on April 18, 2026, directs the FDA and DEA to accelerate psychedelic research for serious mental illness, including breakthrough therapy pathways, national priority vouchers, and ≥ $50 million in federal funding. In an HCPLive interview, Gus Alva, MD, of ATP Clinical Research, highlighted 5-HT2A–mediated neuroplasticity and models such as REBUS as potential mechanisms. Evidence from psilocybin (TRD) and MDMA (PTSD) trials shows promise, though blinding challenges, safety risks, and psychotherapy confounders remain key limitations.

Using AI As a Therapist

Your Patient's New Therapist Is an AI. Now What?

As patients increasingly use ChatGPT for mental health advice, psychiatrists and ethicists warn of clinical and ethical risks. Richard Miller (Elwyn Adult Behavioral Health) noted AI may deliver decontextualized or misleading guidance, while Dominic Sisti (University of Pennsylvania) raised concerns about self-harm queries, privacy, and the need for guardrails. Darlene King (University of Texas Southwestern Medical Center) likened AI advice to that of an uninformed friend.

Despite risks, AI tools show promise in screening, biomarker-guided treatment, and documentation. Experts recommend clinicians proactively discuss AI use and maintain a “human-in-the-loop” approach.

Related:

Patients Bring ChatGPT to Psychiatry Visits, With Richard Miller, MD

AI in Psychiatry Raises Ethics Questions With Dominic Sisti, PhD

Recent Phase 2 Depression Data

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

In a phase 2b trial, single-day inhaled GH001 demonstrated rapid, clinically meaningful antidepressant effects in treatment-resistant depression (TRD), with significant MADRS improvement by day 8 (−15.5; P <.001) and 57.5% remission vs 0% with placebo. In an HCPLive interview, Michael E. Thase (Perelman School of Medicine at the University of Pennsylvania) highlighted GH001’s individualized, single-day dosing (6 mg, 12 mg, 18 mg) and rapid onset within 1 week.

Effects were short-lived (9-14 minutes), with outpatient feasibility. Safety was favorable, with no serious adverse events. Durability data suggest intermittent retreatment approximately every 6 weeks may maintain response.

Kv7 Channel Modulator Azetukalner May Improve Anhedonia, With James Murrough, MD, PhD

At the Anxiety and Depression Association of America (ADAA) 2026 meeting, phase 2 data showed the Kv7 channel opener azetukalner may improve anhedonia in major depressive disorder (MDD) despite missing its primary neuroimaging endpoint. In the randomized trial (n = 60), ventral striatal activation did not differ from placebo, but MADRS and SHAPS outcomes numerically favored azetukalner with low discontinuation rates. James Murrough (Icahn School of Medicine at Mount Sinai) emphasized Kv7 (KCNQ) channels as targets for reward circuitry and stress resilience.